MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V. Read the full story
MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V. Read the full story
MorphoSys and Lanthio Pharma acquires of Lanthio Pharma's lanthipeptide technology, which will be used for drug discovery by MorphoSys. Read the full story
The Partnering Agreements with Morphosys report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies. Read the full story
MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy. Read the full story
MorphoSys has announced only one acquisition in the past 5 years. Read the full story
Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications. Read the full story
MorphoSys, a big pharma, and Celgene, a big pharma and big biotech, announced pharma deals to jointly develop MOR202 globally and to co-promote MOR202 in Europe. Read the full story